Affordable Drugs and Human Freedom vs. American Federalism

March 30, 2018

By David Flemming

For many years, Vermonters have included themselves among the Americans who have been held hostage by the the artificially high prices for pharmaceutical drugs, brought about by the collusion between our federal government and pharmaceutical companies. Senate bill S175 would attempt to alleviate the painful price gouging for Vermonters and is awaiting action in the House after a unanimous vote in the Senate. It directs Vermont’s Agency of Human Services to “design a wholesale prescription drug importation program…us(ing) Canadian prescription drug suppliers.” There have been few Vermont bills in recent memory that have lead to so many fascinating questions about the interplay between federal and state government.

WebMD has a helpful synopsis showing how Americans have already begun importing drugs without respect for the federal statute: “While the practice of reimporting drugs from Canada, Mexico, or other countries is still technically illegal… is increasingly becoming a custom more honored in the breach than in the observance. The U.S. House of Representatives has passed three versions of bills that would allow consumers to import legal drugs for personal use.” While none of these bills have yet to pass through the Senate and the President, it is clear that there is real Congressional and Presidential momentum behind the federal efforts. So far, to no avail: the yearning for a more competitive drug market with more affordable prices has not been realized by Americans at large.

Under federal law, importing drugs from foreign countries is illegal. But due to the sky-high costs of legal prescription drugs in the US, our government Is turning a blind eye to the free-market solution: letting US citizens find lower-cost suppliers abroad and giving them their business. This practice is very much in line with 6 out of 7 of the Ethan Allen Institute’s fundamentals of a free society which are “individual liberty, private property, competitive free enterprise, strong local communities, personal responsibility, and expanded opportunity for human endeavor.”

The EAI fundamental of ‘limited government’ would seem to be in direct conflict with S175. Under American federalism, the federal government has the ultimate authority over matters such as drug commerce (Section 1, Article 9 of the US Constitution), and the states and people are left with the authority not relinquished to the federal government (10th Amendment).

And here is the rub. Special interests (ie prescription drug companies) have abused the complexities of federal government to isolate themselves from competition, but their situation is more precarious at the state level. So it is up to the states, like Vermont, to secure the competitive free enterprise that has been limited by a monolithic, lackadaisical federal government

If a government is to be respected, it must have respectable laws. But the commerce clause in the US Constitution, that the government shall make commerce “regular,” has become less respectable with age, and an open invitation to cronyism. We might feign surprise that people are breaking the law in order to pay less for drugs that sustain their lives, but 21st century innovations and the hundredfold increase in trade in the past 200 years has made selective enforcement of the commerce clause for favored companies the federal government’s only recourse. In the meantime, the rule of law has become less respectable. Supporting the rule of law as defined in our Constitution is important, but not when that support leads to nepotism and severe curtailing of free enterprise and human freedom.

If the federal government already turns a blind eye to, and perhaps hopes, that Americans will have the survival instinct to buck the law by importing foreign drugs, the damage to the rule of law has already been done. Giving Vermont legislators the means to tear down this corrupt federal sanctuary through S175 could do much for enabling human freedom, while re-establishing a responsive and respected statewide government in the absence of a federal one.

Assuming of course, that S175 can appropriate the $1 million needed to fund the program without raising taxes, while giving any Vermont business the chance to import prescription drugs from Canada so as not to create a government sponsored importing monopoly for one business.

{ 2 comments… read them below or add one }

Doug Ricnmond March 31, 2018 at 2:25 am

Almost no other countries will pay the million$ and billion$ needed to get thru a terribly aggressive testing period, both time and delay in getting medications to market.

Since only a handful of nations will pay for research, development and the absurd testing…………

Then we in the USA have to pay the piper – or shut off the spigot of research and medical, surgical, treatment protocols.


Allan Morrie March 31, 2018 at 8:03 pm

The drug companies are profiting billons off of the hard working and retired citizens. The drug companies over pay the executives and over state how much it costs to develop the drugs.
If other countries can sell their drugs for much less than the United States, then the drug companies are profiting way too much money.


Leave a Comment

Previous post:

Next post:

About Us

The Ethan Allen Institute is Vermont’s free-market public policy research and education organization. Founded in 1993, we are one of fifty-plus similar but independent state-level, public policy organizations around the country which exchange ideas and information through the State Policy Network.

Latest News

VT Left Wing Media Bias Unmasks Itself

July 24, 2020 By Rob Roper Dave Gram was a long time reporter for the Associated Press, is currently the host of what’s billed on WDEV as a...

Using Guns for Self Defense – 3 Recent Examples

July 24, 2020 By John McClaughry  The Heritage Foundation’s Daily Signal last week published eleven news stories about citizens using a firearm to stop a crime. Here are...

FERC ruling on solar subsidies could help Vermont ratepayers

July 21, 2020 By John McClaughry Last Thursday, the Federal Energy Regulatory Commission finalized its updates to the Public Utility Regulatory Policies Act (PURPA), in what the majority...

The Moderate Left’s Stand for Free Speech

July 17, 2020 By David Flemming Harper’s Magazine, a long-running monthly magazine of literature, politics, culture, finance, and the arts, is hardly what you would call a ‘politically...

Trump’s Regulatory Bill of Rights

July 16, 2020 by John McClaughry “President Trump [last May] issued an executive order entitled  ‘Regulatory Relief to Support Economic Recovery.’ The executive order includes a regulatory bill...